Non-segmental vitiligo (NSV) is a chronic autoimmune skin disease marked by melanocyte loss and depigmented macules. While clinical features are well recognized, immunohistological correlates such as Melan-A expression and CD8⁺ T-cell infiltration remain undercharacterized. To examine the clinical, histological, and immunohistochemical features of NSV, with a focus on their relationship to disease severity. In this prospective case-control study, 25 NSV patients and 25 matched healthy controls were evaluated using standardized scoring systems (VASI, VIDA, VETF, VETI). Biopsies from lesional, marginal, and normal skin underwent immunohistochemical staining for Melan-A and CD8⁺ T cells. Histopathological changes were graded using a structured scoring system. Lesional skin exhibited significant melanocyte loss (Melan-A⁺ median: 5 [IQR: 3–8]) and elevated CD8⁺ T-cell infiltration (median: 15 [10–18]) compared to controls (p < 0.001). Marginal zones showed intermediate values, indicating subclinical immune activation. CD8⁺ infiltration positively correlated with VASI (r = 0.53), while Melan-A expression showed a negative correlation (r = − 0.55). Both markers were independent predictors of disease severity. NSV exhibits a spatial immunohistological gradient, where melanocyte loss and CD8⁺ T-cell infiltration parallel clinical severity. The integration of immunophenotyping with clinical scoring provides a novel biomarker strategy for personalized therapy.
20 March 2016 in Journal of Turkish Society of Obstetric and Gynecology
Ovarian metasteses are often mistaken for primary adenocarcinoma. Studies conducted in recent years have focused on a search for an immunohistochemical marker to aid the differential diagnosis primary and metastatic ovarian carcinoma. Our study objective was to study the usefulness of Wilms tumor 1 (WT 1) antigen in this context. The study was conducted at the pathology clinic of Lütfi Kırdar Training and Research Hospital. Deparaffinated blocks of 40 epithelial ovarian tumors, 40 colon adenocarcinomas, and 35 cases of omentum metastases were studied. Cytokeratin 7 (CK 7), cytokeratin 20 (CK 20), and WT 1 were applied to all specimens. All ovarian adenocarcinomas were stained with CK 7 (100%). Colorectal adenocarcinomas were stained positive with CK 20 in 87.5% of cases. Primary ovarian adenocarcinomas stained positive with WT 1 in 82.5% of the cases and none of the colorectal adenocarcinomas showed staining with WT 1 (0%). WT 1 can be used in conjuction with CK 7 in the differential diagnosis of ovarian carcinomas.
Objectives: Gastric carcinoma (GC) is the fourth most common cause of cancer-related tumor deaths worldwide. The prognostic significance of CD44, CD133 and human epidermal growth factor receptor 2 (HER2) expression in GC remains controversial. Therefore, we aimed to investigate the relationship of CD44, CD133 and HER2 expression with clinicopathological features in metastatic and non-metastatic GC patients. Methods: A total of 139 patients with GC (68 with metastasis, 71 without metastasis) diagnosed were retrospectively analyzed. CD44 and CD133 expression were determined by immunohistochemical method in all cases. In addition, HER2 overexpression of the tumor was evaluated in patients with metastatic GC. Results: The CD133 positivity rate was 90.6% (n = 126) when all cases were considered, and that for CD44 was 84.9% (n = 118). There was no difference in CD133 and CD44 positivity (intensity or density) rates and between the total scores of metastatic and non-metastatic patients with GC (p > 0.05). HER2 positivity in metastatic cases was detected in 49 (70.1%) patients by immunohistochemical method. No correlation was found between CD133 total score and age, tumor size or depth, and HER2 scores in metastatic or non-metastatic cases (p > 0.05). In the correlation analyzes performed with CD44 scores, only a borderline significant correlation was found between CD44 scores and tumor size (r:0.175; p = 0.047) in non-metastatic cases. Conclusions: We demonstrated associations between CD44/CD133 expression and histological grade in all patients, between CD44 and tumor size in non-metastatic patients, and between HER2 and intestinal type (Lauren) in metastatic patients. The results of this study need to be confirmed by multicenter studies including large case series.